Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 163 Breast Neoplasms 162 Carcinoma, Non-Small-Cell Lung 60 Melanoma 44 Ovarian Neoplasms 42 Colorectal Neoplasms 37 Carcinoma, Renal Cell 36 Squamous Cell Carcinoma of Head and Neck 33 Pancreatic Neoplasms 29 Stomach Neoplasms 28 Neoplasm Metastasis 27 Uterine Cervical Neoplasms 24 Neoplasms 24 Endometrial Neoplasms 24 Lung Neoplasms 19 Head and Neck Neoplasms 19 Esophageal Neoplasms 18 Carcinoma, Transitional Cell 18 Carcinoma, Hepatocellular 16 Urinary Bladder Neoplasms 14 Small Cell Lung Carcinoma 14 Prostatic Neoplasms 14 Parkinson Disease 4, Autosomal Dominant Lewy Body 13 Sarcoma 10 Mesothelioma 9 Kidney Neoplasms 9 Cholangiocarcinoma 9 Carcinoma, Ovarian Epithelial 9 Carcinoma, Merkel Cell 9 Fallopian Tube Neoplasms 8

Interventions

Fulvestrant 19 Letrozole 10 Anastrozole 8 Capecitabine 5 palbociclib 4 olaparib 4 Paclitaxel 4 Injections 4 Goserelin 4 Docetaxel 4 trastuzumab deruxtecan 3 pyrotinib 3 exemestane 3 Vinorelbine 3 Aromatase Inhibitors 3 toripalimab 2 sacituzumab govitecan 2 ribociclib 2 eribulin 2 elacestrant 2 dalpiciclib 2 abemaciclib 2 Trastuzumab 2 Gonadotropin-Releasing Hormone 2 FCN-437c 2 Everolimus 2 Dasatinib 2 Alpelisib 2 Albumin-Bound Paclitaxel 2 AZD9833 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Breast Cancer × pembrolizumab × Breast × Clear all

NCT03025880 2023-04-03

PANGEA

Spanish Breast Cancer Research Group

Phase 2 Completed

36 enrolled 28 charts

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡